



## FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

October 30, 2020

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

Scrip Code: 531599

Symbol: FDC

### Subject: Press Release

Please find attached herewith the Press Release issued in relation to Launch of stronger versions of Favipiravir Drug (PiFLU and Favenza) meant to treat mild to moderate cases of Covid 19.

The same is published in newspapers in across India.

Kindly take the same on record.

Thanking you,

Yours truly,

For FDC LIMITED

VARSHARANI  
RAJARAM KATRE  
Date: 2020.10.30 16:52:25  
+05'30'

Varsharani Katre  
Company Secretary  
F-8948



CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA  
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

## FDC LIMITED INTRODUCES STRONGER VERSIONS OF FAVIPIRAVIR DRUGS PiFLU and FAVENZA

*~ stronger variant – PiFLU-800 & Favenza-800 – helps reduce dosage frequency as well as cost ~*

**Mumbai, 29.10.2020:** Home-grown pharma major, [FDC Limited](#), today announced the launch of new strength variants of its Favipiravir brands – **PiFLU** and **Favenza**, **used to treat mild to moderate cases of COVID-19 in India**. These prescription-only drugs will be **available at all retail medical outlets and hospital pharmacies across the country, from 1<sup>st</sup> of November, 2020**.

The 800mg version of the drugs will **help reduce the number of tablets to be taken by any patient by 75%**. *Currently patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days.*

Commenting on the development, **Mr. Mayank Tikkha from FDC Limited** said, *“Post the launch of PiFLU and Favenza in August, we decided to work on reducing the dosage frequency as well as the cost as a result of which we have introduced this variant. PiFLU-800 and Favenza-800 will help patients reduce the cost of therapy by 30% while strengthening efficacy of treatment. This makes life very convenient and cost-effective for patients who are home quarantined, and being treated by family physicians”*.

Drug Controller General of India (DCGI)-approved Favipiravir is a broad spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication. **PiFLU and Favenza reduces progression to severe or critical conditions of COVID-19 in 92.5% of cases by Day 10, and 62.5% at Day 5**. It has also helped **show significant improvement in Chest CT score in 90% of patients by Day 15**.

This oral anti-viral drug has been shown reducing the viral replication cycle leading to quicker clinical recovery in COVID-19 patients with mild to moderate symptoms. With innovations such as these, FDC continues to stand by India in our fight against COVID-19!

### **ABOUT FDC LIMITED**

[FDC Limited](#) is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDC's formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. FDC has set-up globally approved, multi-location manufacturing facilities at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. Some of its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.